Veeva Systems Inc. (NYSE:VEEV) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Veeva Systems Inc. (NYSE:VEEV - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-five ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $254.92.

VEEV has been the subject of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and issued a $270.00 price objective on shares of Veeva Systems in a research report on Thursday, March 6th. Morgan Stanley boosted their price objective on Veeva Systems from $195.00 to $201.00 and gave the company an "underweight" rating in a research report on Thursday, March 6th. Robert W. Baird boosted their price target on Veeva Systems from $283.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, March 6th. KeyCorp dropped their price target on Veeva Systems from $260.00 to $250.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Finally, Stephens reiterated an "overweight" rating and set a $280.00 price target on shares of Veeva Systems in a research report on Thursday, March 6th.

Insider Activity

In other news, SVP Jonathan Faddis sold 787 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $226.20, for a total value of $178,019.40. Following the transaction, the senior vice president now owns 8,668 shares of the company's stock, valued at $1,960,701.60. This represents a 8.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy S. Cabral sold 3,882 shares of the company's stock in a transaction on Friday, April 4th. The shares were sold at an average price of $216.83, for a total value of $841,734.06. Following the completion of the transaction, the director now directly owns 5,500 shares in the company, valued at approximately $1,192,565. This trade represents a 41.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,869 shares of company stock valued at $1,284,917 in the last quarter. Insiders own 10.30% of the company's stock.

Hedge Funds Weigh In On Veeva Systems

Hedge funds have recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB lifted its stake in Veeva Systems by 72.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company's stock worth $25,000 after acquiring an additional 50 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Veeva Systems during the 4th quarter worth about $25,000. Abound Financial LLC acquired a new position in Veeva Systems during the 1st quarter worth about $25,000. ORG Partners LLC acquired a new position in Veeva Systems during the 1st quarter worth about $26,000. Finally, Smithfield Trust Co lifted its stake in Veeva Systems by 145.5% during the 4th quarter. Smithfield Trust Co now owns 135 shares of the technology company's stock worth $27,000 after acquiring an additional 80 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company's stock.

Veeva Systems Price Performance

Veeva Systems stock opened at $242.48 on Friday. The stock has a market capitalization of $39.45 billion, a PE ratio of 59.87, a price-to-earnings-growth ratio of 1.89 and a beta of 0.96. Veeva Systems has a 12 month low of $170.25 and a 12 month high of $258.93. The business has a 50 day simple moving average of $228.63 and a 200-day simple moving average of $226.29.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.